Nippon Shinyaku Co Ltd 2023 IR
The report highlights Nippon Shinyaku's financial and non-financial performance for fiscal year 2022. Key achievements include record-high consolidated revenue for the 13th consecutive year, the launch of Fintepla for Dravet syndrome, and MonoVer for iron deficiency anemia. The company also established the Innovation Research Partnering office in Cambridge, USA, to accelerate drug discovery. On the sustainability front, Nippon Shinyaku revised its issues of materiality, reduced Scope 1 and 2 greenhouse gas emissions by 5.2% year on year, and increased the male childcare leave uptake rate to 69.3%.
Company: Nippon Shinyaku Co Ltd
Sector: Health Care
Country: Japan
Year: 2023
Type: IR
Pages: 46
Nippon Shinyaku Co Ltd
Integrated Report
The report highlights Nippon Shinyaku's financial and non-financial performance for fiscal year 2022. Key achievements include record-high consolidated revenue for the 13th consecutive year, the launch of Fintepla for Dravet syndrome, and MonoVer for iron deficiency anemia. The company also established the Innovation Research Partnering office in Cambridge, USA, to accelerate drug discovery. On the sustainability front, Nippon Shinyaku revised its issues of materiality, reduced Scope 1 and 2 greenhouse gas emissions by 5.2% year on year, and increased the male childcare leave uptake rate to 69.3%.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Apr 1, 2022 - Mar 31, 2023
Fiscal Year
2022
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Net Zero Target
Employees